$ATOS
ATOSSA THERAPEUTICS, INC.

2023 Q2 Form 10-Q Financial Statement

#000143774923014366 Filed on May 15, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.088M $3.590M
YoY Change 29.29% 10.5%
% of Gross Profit
Research & Development $3.705M $3.508M
YoY Change 7.92% 134.02%
% of Gross Profit
Depreciation & Amortization $3.000K $3.000K
YoY Change 50.0% 50.0%
% of Gross Profit
Operating Expenses $7.793M $7.098M
YoY Change 18.17% 49.53%
Operating Profit -$7.793M -$7.098M
YoY Change 18.17% 49.53%
Interest Expense $983.0K $821.0K
YoY Change -1256.47% -2931.03%
% of Operating Profit
Other Income/Expense, Net -$30.00K -$33.00K
YoY Change -61.04% -15.38%
Pretax Income -$9.830M -$6.281M
YoY Change 47.33% 31.24%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$9.830M -$6.281M
YoY Change 47.33% 31.26%
Net Earnings / Revenue
Basic Earnings Per Share -$0.08 -$0.05
Diluted Earnings Per Share -$0.08 -$0.05
COMMON SHARES
Basic Shares Outstanding 126.6M 126.6M
Diluted Shares Outstanding 126.6M 126.6M

Balance Sheet

Concept 2023 Q2 2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $99.39M $103.9M
YoY Change -20.83% -21.0%
Cash & Equivalents $99.39M $103.9M
Short-Term Investments
Other Short-Term Assets $7.000K $858.0K
YoY Change -99.55% 20.85%
Inventory
Prepaid Expenses $5.759M $5.295M
Receivables
Other Receivables
Total Short-Term Assets $106.0M $110.9M
YoY Change -20.55% -18.98%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $1.710M $4.700M
YoY Change
Other Assets $642.0K $631.0K
YoY Change 2.39% 0.16%
Total Long-Term Assets $2.352M $5.331M
YoY Change 275.12% 746.19%
TOTAL ASSETS
Total Short-Term Assets $106.0M $110.9M
Total Long-Term Assets $2.352M $5.331M
Total Assets $108.4M $116.2M
YoY Change -19.17% -15.48%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.174M $1.444M
YoY Change -42.79% -9.52%
Accrued Expenses $803.0K $613.0K
YoY Change -3.72% 410.83%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $3.478M $2.944M
YoY Change -8.28% 26.79%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $3.478M $2.944M
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $3.478M $2.944M
YoY Change -8.28% 26.79%
SHAREHOLDERS EQUITY
Retained Earnings -$172.3M -$162.5M
YoY Change 22.47% 21.23%
Common Stock $276.8M $275.1M
YoY Change 2.36% 2.44%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $104.9M $113.3M
YoY Change
Total Liabilities & Shareholders Equity $108.4M $116.2M
YoY Change -19.17% -15.48%

Cashflow Statement

Concept 2023 Q2 2023 Q1
OPERATING ACTIVITIES
Net Income -$9.830M -$6.281M
YoY Change 47.33% 31.26%
Depreciation, Depletion And Amortization $3.000K $3.000K
YoY Change 50.0% 50.0%
Cash From Operating Activities -$4.465M -$7.022M
YoY Change -24.95% 43.95%
INVESTING ACTIVITIES
Capital Expenditures $13.00K $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$13.00K $0.00
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 $0.00
YoY Change
NET CHANGE
Cash From Operating Activities -4.465M -$7.022M
Cash From Investing Activities -13.00K $0.00
Cash From Financing Activities 0.000 $0.00
Net Change In Cash -4.478M -$7.022M
YoY Change -24.73% 43.57%
FREE CASH FLOW
Cash From Operating Activities -$4.465M -$7.022M
Capital Expenditures $13.00K $0.00
Free Cash Flow -$4.478M -$7.022M
YoY Change -24.73% 43.57%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-4747000 usd
CY2023Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
850000 usd
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
1000
CY2023Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
1000
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
1000
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
1000
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.18
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.18
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
175000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
175000000
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
126624000
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
126624000
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
126624000
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
126624000
CY2023Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 pure
CY2022Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
110000 usd
CY2023Q1 atos Class Of Warrant Or Right Exercised During Period
ClassOfWarrantOrRightExercisedDuringPeriod
0
CY2022Q1 atos Class Of Warrant Or Right Exercised During Period
ClassOfWarrantOrRightExercisedDuringPeriod
0
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
001-35610
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
26-4753208
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
107 Spring Street
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
98104
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Seattle
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
WA
CY2023Q1 dei City Area Code
CityAreaCode
206
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
588-0256
CY2023Q1 dei Security12b Title
Security12bTitle
Common Stock, $0.18 par value
CY2023Q1 dei Trading Symbol
TradingSymbol
ATOS
CY2023Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
126624110
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
103868000 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
110890000 usd
CY2023Q1 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
110000 usd
CY2022Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
110000 usd
CY2023Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
5295000 usd
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
4031000 usd
CY2023Q1 atos Research And Development Tax Rebate Receivable
ResearchAndDevelopmentTaxRebateReceivable
738000 usd
CY2022Q4 atos Research And Development Tax Rebate Receivable
ResearchAndDevelopmentTaxRebateReceivable
743000 usd
CY2023Q1 us-gaap Other Assets Current
OtherAssetsCurrent
858000 usd
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
2423000 usd
CY2023Q1 us-gaap Assets Current
AssetsCurrent
110869000 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
118197000 usd
CY2023Q1 us-gaap Equity Securities Without Readily Determinable Fair Value Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
4700000 usd
CY2022Q4 us-gaap Equity Securities Without Readily Determinable Fair Value Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
4700000 usd
CY2023Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
631000 usd
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
635000 usd
CY2023Q1 us-gaap Assets
Assets
116200000 usd
CY2022Q4 us-gaap Assets
Assets
123532000 usd
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
1444000 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2965000 usd
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
613000 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1059000 usd
CY2023Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
822000 usd
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1525000 usd
CY2023Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
65000 usd
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
19000 usd
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
2944000 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
5568000 usd
CY2023Q1 us-gaap Liabilities
Liabilities
2944000 usd
CY2022Q4 us-gaap Liabilities
Liabilities
5568000 usd
CY2023Q1 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
22792000 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
22792000 usd
CY2023Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
252357000 usd
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
250784000 usd
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-162475000 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-156194000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
113256000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
117964000 usd
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
116200000 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
123532000 usd
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3508000 usd
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1499000 usd
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3590000 usd
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3248000 usd
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
7098000 usd
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
4747000 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-7098000 usd
CY2022Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
1000 usd
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-33000 usd
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-40000 usd
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-6281000 usd
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-4786000 usd
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-6281000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-4786000 usd
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.05
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.04
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
126624000
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
126624000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
138136000 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1806000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-4786000 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
135156000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
117964000 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1573000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-6281000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
113256000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-6281000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-4786000 usd
CY2023Q1 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
1573000 usd
CY2022Q1 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
1806000 usd
CY2023Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
3000 usd
CY2022Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2000 usd
CY2023Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
1264000 usd
CY2022Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
1386000 usd
CY2023Q1 atos Increase Decrease In Research And Development Tax Rebate Receivable
IncreaseDecreaseInResearchAndDevelopmentTaxRebateReceivable
-5000 usd
CY2022Q1 atos Increase Decrease In Research And Development Tax Rebate Receivable
IncreaseDecreaseInResearchAndDevelopmentTaxRebateReceivable
-404000 usd
CY2023Q1 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-1565000 usd
CY2022Q1 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
114000 usd
CY2023Q1 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-1000 usd
CY2022Q1 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-0 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1521000 usd
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-121000 usd
CY2023Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-446000 usd
CY2022Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-84000 usd
CY2023Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-703000 usd
CY2022Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-591000 usd
CY2023Q1 us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
46000 usd
CY2022Q1 us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
-8000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7022000 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4878000 usd
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
-0 usd
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
13000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-13000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-7022000 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-4891000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
111000000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
136487000 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
103978000 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
131596000 usd
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
103868000 usd
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
131486000 usd
CY2023Q1 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
110000 usd
CY2022Q1 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
110000 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
103978000 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
131596000 usd
CY2023Q1 us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><b>NOTE <em style="font: inherit;">1:</em> NATURE OF OPERATIONS</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-variant-numeric: normal; font-variant-east-asian: normal; margin: 0pt; text-indent: 54pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Atossa Therapeutics, Inc. (the Company) was incorporated on <em style="font: inherit;"> April 30, 2009, </em>in the State of Delaware to develop and market medical devices, laboratory tests and therapeutics to address breast health conditions. The Company is currently focused on developing proprietary innovative medicines in areas of significant unmet medical need in oncology, with a current focus on breast cancer and other breast conditions. The Company's fiscal year ends on <em style="font: inherit;"> December 31.</em></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 54pt;"> </p>
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-6281000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7022000 usd
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
103868000 usd
CY2023Q1 atos Working Capital Deficit
WorkingCapitalDeficit
107925000 usd
CY2023Q1 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 54pt;"><b><i>Reclassification </i></b></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 54pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 54pt;">Interest income has been reclassified from prior period amounts to conform to the current year presentation.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 54pt;"> </p>
CY2022Q4 us-gaap Prepaid Insurance
PrepaidInsurance
387000 usd
CY2023Q1 atos Professional Services Current
ProfessionalServicesCurrent
138000 usd
CY2022Q4 atos Professional Services Current
ProfessionalServicesCurrent
130000 usd
CY2023Q1 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
18000 usd
CY2023Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 54pt;"><i><b> Estimates</b></i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -3pt; text-indent: 54pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:54pt;"> </p>
CY2022Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
34000 usd
CY2023Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
5295000 usd
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
4031000 usd
CY2023Q1 atos Number Of Shares Authorized To Issue
NumberOfSharesAuthorizedToIssue
185000000
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
175000000
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2023Q1 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
110000 usd
CY2023Q1 atos Research And Development Current
ResearchAndDevelopmentCurrent
4619000 usd
CY2022Q4 atos Research And Development Current
ResearchAndDevelopmentCurrent
3480000 usd
CY2023Q1 us-gaap Prepaid Insurance
PrepaidInsurance
520000 usd
CY2023Q1 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
297000 usd
CY2022Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
1060000 usd
CY2023Q1 us-gaap Accrued Vacation Current
AccruedVacationCurrent
278000 usd
CY2022Q4 us-gaap Accrued Vacation Current
AccruedVacationCurrent
224000 usd
CY2023Q1 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
247000 usd
CY2022Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
241000 usd
CY2023Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
822000 usd
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1525000 usd
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.18
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2014Q2 atos Stockholder Rights Agreement Number Of Preferred Stock Right Distributed For Each Share Of Common Stock
StockholderRightsAgreementNumberOfPreferredStockRightDistributedForEachShareOfCommonStock
1
CY2014Q2 atos Stockholder Rights Agreement Acquiring Person Percentage Of Ownership
StockholderRightsAgreementAcquiringPersonPercentageOfOwnership
0.15 pure
CY2014Q2 atos Stockholder Rights Agreement Acquiring Person Additional Percentage Of Ownership
StockholderRightsAgreementAcquiringPersonAdditionalPercentageOfOwnership
0.020 pure
CY2014Q2 atos Stockholder Rights Agreement Initial Exercise Price Of Each Right
StockholderRightsAgreementInitialExercisePriceOfEachRight
15.00
CY2014Q2 atos Stockholder Rights Agreement Share Price
StockholderRightsAgreementSharePrice
30.00
CY2023Q1 atos Consummate A Business Combination Percentage Of Acquired Outstanding Shares
ConsummateABusinessCombinationPercentageOfAcquiredOutstandingShares
0.50 pure
CY2023Q1 atos Consummate A Business Combination Percentage Of Aggregate Ordinary Voting Power
ConsummateABusinessCombinationPercentageOfAggregateOrdinaryVotingPower
0.50 pure
CY2023Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
21515
CY2023Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
21515
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-6281000 usd
CY2022Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-4786000 usd
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
126624000
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
126624000
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.05
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.04
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
36423000
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
33531000
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2023Q1 us-gaap Cash Uninsured Amount
CashUninsuredAmount
103712000 usd
CY2022Q4 us-gaap Cash Uninsured Amount
CashUninsuredAmount
110647000 usd
CY2023Q1 atos Lessee Operating Lease Monthly Rent Payments
LesseeOperatingLeaseMonthlyRentPayments
2000 usd
CY2023Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
4000 usd
CY2022Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
8000 usd
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1573000 usd
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1806000 usd
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
13906000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.35
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0 usd
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2461000
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.72
CY2023Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
-0
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
-0
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
0
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
3000
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
793.83
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
16364000
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.95
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y11M4D
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
44000 usd
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
11227000
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
2.32
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y3M10D
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
11227000
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
1.95
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y11M4D
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
44000 usd
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
5137000
CY2023Q1 us-gaap Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
0.06 pure
CY2023Q1 us-gaap Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
0.06 pure
CY2023Q1 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
56000 usd
CY2022Q1 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
34000 usd

Files In Submission

Name View Source Status
atos-20230331_cal.xml Edgar Link unprocessable
0001437749-23-014366-index-headers.html Edgar Link pending
0001437749-23-014366-index.html Edgar Link pending
0001437749-23-014366.txt Edgar Link pending
0001437749-23-014366-xbrl.zip Edgar Link pending
atos-20230331.xsd Edgar Link pending
atos20230331_10q.htm Edgar Link pending
ex_473330.htm Edgar Link pending
ex_473331.htm Edgar Link pending
ex_473332.htm Edgar Link pending
ex_473333.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
atos-20230331_def.xml Edgar Link unprocessable
atos-20230331_pre.xml Edgar Link unprocessable
atos-20230331_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
atos20230331_10q_htm.xml Edgar Link completed
MetaLinks.json Edgar Link pending
p01.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending